한글목차

세계 항생제 내성 시장은 2025년에 88억 4,000만 달러로 추정되며, 2032년에는 128억 6,000만 달러에 달할 것으로 예상되며, 2025년부터 2032년까지 연평균 5.5%의 CAGR로 성장할 것으로 예상됩니다.

그림. 항생제 내성 세계 시장 점유율(%), 지역별, 2025년

세계 항생제 내성 시장은 최근 몇 년 동안 괄목할 만한 성장을 거듭하고 있습니다. 항생제는 세균 감염의 예방과 치료에 사용되는 의약품입니다. 항생제는 세균을 죽이거나 세균의 증식을 막는 역할을 합니다. 가장 일반적으로 사용되는 항생제에는 페니실린, 아목시실린, 세팔로스포린 등이 있습니다. 그러나 지난 수십 년 동안 항생제 내성은 전 세계적으로 공중보건에 큰 위협이 되고 있습니다. 박테리아가 항생제 내성을 가지게 되면 박테리아가 일으키는 감염을 치료하는 데 사용되는 약물이 효과가 없게 됩니다. 그 결과, 질병이 장기화되고 사망률도 증가합니다. 다양한 항생제 계열에 내성을 가진 박테리아 균주의 증가는 주로 항생제의 오용과 남용으로 인해 발생합니다. 항생제 내성을 촉진하는 다른 요인으로는 새로운 항생제 개발 부족, 세계 여러 지역의 위생 환경 부족, 해외 여행 증가 등을 들 수 있습니다. 항생제 내성은 적절히 대처하지 않으면 심각한 건강 문제를 야기하고 환자의 예후에 영향을 미칠 수 있습니다.

시장 역학:

세계 항생제 내성 시장의 성장은 항생제 내성 감염증의 유병률 증가, 신규 항생제 개발 부족, 기존 항생제의 오용 및 남용, 많은 신흥국 시장에서의 감염 관리 제한 등 다양한 요인에 기인합니다. 그러나 대체 치료법 개발 및 항생제 사용에 대한 엄격한 규제는 시장 성장을 억제할 수 있습니다. 이 시장은 새로운 작용 기전을 가진 새로운 항생제 개발에 집중하는 기업에게 기회가 될 수 있습니다. 주요 기업들은 항생제 내성에 대응하기 위해 파지 요법, 백신, 단클론항체 등 대체 치료법을 모색하고 있습니다. 산학협력은 다가올 헬스케어 위기에 대처하기 위한 유망한 수단입니다.

본 조사의 주요 특징

• 세계의 항생제 내성 시장을 상세히 분석하여 2024년을 기준 연도로 하여 예측 기간(2025-2032년)의 시장 규모와 연평균 성장률(CAGR)을 예측한 보고서입니다.
• 또한, 다양한 부문에 걸친 잠재적인 수익 성장 기회를 밝히고, 이 시장의 매력적인 투자 제안 매트릭스를 설명합니다.
• 또한 시장 촉진요인, 억제요인, 기회, 신제품 출시 및 승인, 시장 동향, 지역별 전망, 주요 기업의 경쟁 전략 등에 대한 중요한 인사이트를 제공합니다.
• 이 보고서는 기업 하이라이트, 제품 포트폴리오, 주요 하이라이트, 재무 성과, 전략 등의 매개 변수를 기반으로 세계 항생제 내성 시장의 주요 기업을 프로파일링합니다.
• 이 보고서의 인사이트를 통해 마케팅 담당자와 기업 경영진은 향후 제품 출시, 유형화, 시장 확대, 마케팅 전술에 대한 정보에 입각한 의사결정을 내릴 수 있습니다.
• 세계 항생제 내성 시장 보고서는 투자자, 공급업체, 제품 제조업체, 유통업체, 신규 진입자, 재무 분석가 등 업계의 다양한 이해관계자를 대상으로 합니다.
• 이해관계자들은 세계 항생제 내성 시장 분석에 사용되는 다양한 전략 매트릭스를 통해 의사결정을 용이하게 할 수 있습니다.

목차

제1장 조사 목적과 가정

• 조사 목적
• 가정
• 약어

제2장 시장 전망

• 보고서 설명
  • 시장 정의와 범위
• 주요 요약
• Coherent Opportunity Map(COM)

제3장 시장 역학, 규제, 동향 분석

• 시장 역학
  • 감염증 만연율 상승
  • 항생제 내성 진단의 진보
  • 증가하는 연구개발 활동
• 주요 하이라이트
• 파견 회사와 파견처 고용주를 위한 가이드라인
• 시장 동향
• PEST 분석
• 투자와 자금 조달
• 합병, 인수 및 제휴
• 제공되는 주요 서비스
• 상위 시장 기업 특정
• 간호사 인원 배치 우위성
• 국가별 헬스케어비 지출

제4장 세계의 항생제 내성 시장 - 코로나바이러스(COVID-19) 팬데믹의 영향

• COVID-19 역학
• 공급측과 수요측 분석
• 경제에 대한 영향

제5장 세계의 항생제 내성 시장 : 약물 종류별, 2020-2032년

• 옥사졸리디논
• 리포글리코펩타이드
• 테트라사이클린
• 세팔로스포린
• 기타(병용요법 등)

제6장 세계의 항생제 내성 시장 : 질환별, 2020-2032년

• cUTI(복잡성 요로감염)
• CDI(클로스트리디오이데스·디피실 감염증)
• ABSSSI(급성 세균성 피부 및 피부 구조 감염증)
• HABP(원내 세균성 폐렴)
• CABP(시중 폐렴)
• cIAI(복잡성 복강내 감염증)
• 기타(BSI(혈류 감염) 등)

제7장 세계의 항생제 내성 시장 : 유통 채널별, 2020-2032년

• 병원 약국
• 소매 약국
• 온라인 약국

제8장 세계의 항생제 내성 시장 : 지역별, 2020-2032년

• 북미
• 유럽
• 아시아태평양
• 라틴아메리카
• 중동
• 아프리카

제9장 경쟁 구도

• 기업 개요
  • Melinta Therapeutics
  • Merck & Co., Inc.
  • Allergan
  • Pfizer Inc.
  • Tetraphase Pharmaceutical, Inc.
  • TeamHealth
  • Theravance Biopharma
  • WOCKHARDT
  • Entasis Threapeutics
  • Paratek Pharmaceutials, Inc.
  • Seres Therapeutics
  • Achaogen Inc.
  • Basilea Pharmaceutical Ltd.
  • Nabriva Threapeutics plc
  • NEMESIS BIOSCIENCE LTD.

제10장 섹션

• 참고문헌
• 조사 방법
• 출판사 소개

영문목차

Global Antibiotic Resistance Market is estimated to be valued at USD 8.84 Bn in 2025 and is expected to reach USD 12.86 Bn by 2032, growing at a compound annual growth rate (CAGR) of 5.5% from 2025 to 2032.

Figure. Global Antibiotic Resistance Market Share (%), By Region 2025

The global antibiotic resistance market has been witnessing significant growth in recent years. Antibiotics are medicines used to prevent and treat bacterial infections. They either kill bacteria or stop them from multiplying. Some of the most commonly used antibiotics include penicillin, amoxicillin, cephalosporins etc. However, over the past few decades, antibiotic resistance has been emerging as a major public health threat globally. When bacteria become antibiotic resistant, the medicines used to treat the infections they cause become ineffective. This leads to longer illness and increased death rates. The rising prevalence of bacterial strains that are resistant to various antibiotic classes is primarily attributable to misuse and overuse of antibiotics. Other factors that drive antibiotic resistance include the lack of development of new antibiotics, lack of sanitation and hygiene in many parts of the world, increased international travels, etc. If not addressed properly, antibiotic resistance could lead to serious health issues and affect patient outcomes.

Market Dynamics:

The global antibiotic resistance market growth is driven by various factors such as increasing prevalence of antibiotic-resistant bacterial infections, lack of new antibiotic development, misuse and overuse of existing antibiotics, limited infection control in many developing regions, etc. However, the development of alternative treatment options and stringent regulations regarding antibiotic usage could restrain the market growth. The market provides opportunities for companies focusing on the development of novel antibiotics with new mechanisms of action. Key players are also exploring alternative therapeutic approaches like phage therapy, vaccines, monoclonal antibodies etc. to counter antibiotic resistance. Partnerships between industry and academia hold promise to address this looming healthcare crisis.

Key Features of the Study:

• This report provides an in-depth analysis of the global antibiotic resistance market, and provides market size (US$ Bn) and compound annual growth rate (CAGR %) for the forecast period (2025-2032), considering 2024 as the base year
• It elucidates potential revenue growth opportunities across different segments and explains attractive investment proposition matrices for this market
• This study also provides key insights about market drivers, restraints, opportunities, new product launches or approvals, market trends, regional outlook, and competitive strategies adopted by key players
• It profiles key players in the global antibiotic resistance market based on the following parameters - company highlights, products portfolio, key highlights, financial performance, and strategies
• Key companies covered as a part of this study include Melinta Therapeutics, Merck & Co., Inc., Allergan, Pfizer Inc., Tetraphase Pharmaceutical, Inc., Theravance Biopharma, WOCKHARDT, Entasis Threapeutics, Paratek Pharmaceutials, Inc., Seres Therapeutics, Achaogen Inc., Basilea Pharmaceutical Ltd., Nabriva Threapeutics plc, NEMESIS BIOSCIENCE LTD.
• Insights from this report would allow marketers and the management authorities of the companies to make informed decisions regarding their future product launches, type up-gradation, market expansion, and marketing tactics
• The global antibiotic resistance market report caters to various stakeholders in this industry including investors, suppliers, product manufacturers, distributors, new entrants, and financial analysts
• Stakeholders would have ease in decision-making through various strategy matrices used in analyzing the global antibiotic resistance market

Detailed Segmentation:

• Global Antibiotic Resistance Market, By Drug Class
  • Oxazolidinones
  • Lipoglycopeptides
  • Tetracyclines
  • Cephalosporins
  • Others (Combination therapies, etc.)
• Global Antibiotic Resistance Market, By Disease
  • cUTI (Complicated Urinary Tract Infections)
  • CDI (Clostridioides difficile Infection)
  • ABSSSI (Acute bacterial skin and skin structure infections)
  • HABP (Hospital-acquired bacterial pneumonia)
  • CABP (Community-acquired pneumonia)
  • cIAI (Complicated intra-abdominal infection)
  • Others (BSI (Bloodstream infection), etc.)
• Global Antibiotic Resistance Market, By Distribution Channel
  • Hospital Pharmacies
  • Retail Pharmacies
  • Online Pharmacies
• Global Antibiotic Resistance Market, By Region
  • North America
  • Europe
  • Asia Pacific
  • Latin America
  • Middle East
  • Africa
• Company Profiles
  • Melinta Therapeutics
  • Merck & Co., Inc.
  • Allergan
  • Pfizer Inc.
  • Tetraphase Pharmaceutical, Inc.
  • Theravance Biopharma
  • WOCKHARDT
  • Entasis Threapeutics
  • Paratek Pharmaceutials, Inc.
  • Seres Therapeutics
  • Achaogen Inc.
  • Basilea Pharmaceutical Ltd.
  • Nabriva Threapeutics plc
  • NEMESIS BIOSCIENCE LTD.

Table of Contents

1. Research Objectives and Assumptions

• Research Objectives
• Assumptions
• Abbreviations

2. Market Purview

• Report Description
  • Market Definition and Scope
• Executive Summary
  • Market Snippet, By Drug Class
  • Market Snippet, By Disease
  • Market Snippet, By Distribution Channel
  • Market Snippet, By Region
• Coherent Opportunity Map (COM)

3. Market Dynamics, Regulations, and Trends Analysis

• Market Dynamics
  • Rising prevalence of infectious diseases
  • Advancement in antibiotic resistance diagnosis
  • Growing number of R&D activities
• Key Highlights
• Guidelines for the Temporary Staffing Agency & the Host Employer
• Market Trends
• PEST Analysis
• Investments and Fundings
• Mergers, Acquisitions, and Collaborations
• Key Services Offered
• Identification of Top Market Players
• Nurse Staffing Dominance
• Healthcare Spending by Country

4. Global Antibiotic Resistance Market - Impact of Coronavirus (COVID-19) Pandemic

• COVID-19 Epidemiology
• Supply Side and Demand Side Analysis
• Economic Impact

5. Global Antibiotic Resistance Market, By Drug Class, 2020-2032, (US$ Bn)

• Introduction
  • Market Share Analysis, 2025 and 2032 (%)
  • Y-o-Y Growth Analysis, 2021 - 2032
  • Segment Trends
• Oxazolidinones
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (US$ Bn)
• Lipoglycopeptides
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (US$ Bn)
• Tetracyclines
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (US$ Bn)
• Cephalosporins
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (US$ Bn)
• Others (Combination therapies, etc.)
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (US$ Bn)

6. Global Antibiotic Resistance Market, By Disease, 2020-2032, (US$ Bn)

• Introduction
  • Market Share Analysis, 2025 and 2032 (%)
  • Y-o-Y Growth Analysis, 2021 - 2032
  • Segment Trends
• cUTI (Complicated Urinary Tract Infections)
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (US$ Bn)
• CDI (Clostridioides difficile Infection)
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (US$ Bn)
• ABSSSI (Acute bacterial skin and skin structure infections)
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (US$ Bn)
• HABP (Hospital-acquired bacterial pneumonia)
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (US$ Bn)
• CABP (Community-acquired pneumonia)
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (US$ Bn)
• cIAI (Complicated intra-abdominal infection)
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (US$ Bn)
• Others (BSI (Bloodstream infection), etc.)
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (US$ Bn)

7. Global Antibiotic Resistance Market, By Distribution Channel, 2020-2032, (US$ Bn)

• Introduction
  • Market Share Analysis, 2025 and 2032 (%)
  • Y-o-Y Growth Analysis, 2021 - 2032
  • Segment Trends
• Hospital Pharmacies
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (US$ Bn)
• Retail Pharmacies
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (US$ Bn)
• Online Pharmacies
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (US$ Bn)

8. Global Antibiotic Resistance Market, By Region, 2020-2032, (US$ Bn)

• Introduction
  • Market Share Analysis, By Region, 2025 and 2032 (%)
  • Y-o-Y Growth Analysis, For Region, 2021 - 2032
  • Country Trends
• North America
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, By Drug Class, 2020-2032, (US$ Bn)
  • Market Size and Forecast, and Y-o-Y Growth, By Disease, 2020-2032, (US$ Bn)
  • Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2020-2032, (US$ Bn)
  • Market Size and Forecast, and Y-o-Y Growth, By Country, 2020-2032, (US$ Bn)
    • U.S.
    • Canada
• Europe
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, By Drug Class, 2020-2032, (US$ Bn)
  • Market Size and Forecast, and Y-o-Y Growth, By Disease, 2020-2032, (US$ Bn)
  • Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2020-2032, (US$ Bn)
  • Market Size and Forecast, and Y-o-Y Growth, By Country, 2020-2032, (US$ Bn)
    • Germany
    • U.K.
    • Spain
    • France
    • Italy
    • Russia
    • Rest of Europe
• Asia Pacific
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, By Drug Class, 2020-2032, (US$ Bn)
  • Market Size and Forecast, and Y-o-Y Growth, By Disease, 2020-2032, (US$ Bn)
  • Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2020-2032, (US$ Bn)
  • Market Size and Forecast, and Y-o-Y Growth, By Country, 2020-2032, (US$ Bn)
    • China
    • India
    • Japan
    • Australia
    • South Korea
    • ASEAN
    • Rest of Asia Pacific
• Latin America
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, By Drug Class, 2020-2032, (US$ Bn)
  • Market Size and Forecast, and Y-o-Y Growth, By Disease, 2020-2032, (US$ Bn)
  • Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2020-2032, (US$ Bn)
  • Market Size and Forecast, and Y-o-Y Growth, By Country, 2020-2032, (US$ Bn)
    • Brazil
    • Argentina
    • Mexico
    • Rest of Latin America
• Middle East
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, By Drug Class, 2020-2032, (US$ Bn)
  • Market Size and Forecast, and Y-o-Y Growth, By Disease, 2020-2032, (US$ Bn)
  • Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2020-2032, (US$ Bn)
  • Market Size and Forecast, and Y-o-Y Growth, By Country, 2020-2032, (US$ Bn)
    • GCC Countries
    • Israel
    • Rest of Middle East
• Africa
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, By Drug Class, 2020-2032, (US$ Bn)
  • Market Size and Forecast, and Y-o-Y Growth, By Disease, 2020-2032, (US$ Bn)
  • Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2020-2032, (US$ Bn)
  • Market Size and Forecast, and Y-o-Y Growth, By Country/Region, 2020-2032, (US$ Bn)
    • North Africa
    • Central Africa
    • South Africa

9. Competitive Landscape

• Company Profile
  • Melinta Therapeutics
• Company Highlights
• Product Portfolio
• Key Highlights
• Financial Performance
• Strategies
  • Merck & Co., Inc.
  • Allergan
  • Pfizer Inc.
  • Tetraphase Pharmaceutical, Inc.
  • TeamHealth
  • Theravance Biopharma
  • WOCKHARDT
  • Entasis Threapeutics
  • Paratek Pharmaceutials, Inc.
  • Seres Therapeutics
  • Achaogen Inc.
  • Basilea Pharmaceutical Ltd.
  • Nabriva Threapeutics plc
  • NEMESIS BIOSCIENCE LTD.
• Analyst Views

10. Section

• References
• Research Methodology
• About us